AC
JANX icon

AXQ Capital’s Janux Therapeutics JANX Stock Holding History

AXQ Capital’s Portfolio JANX Stock Details JANX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$730K Buy
47,508
+24,777
+109% +$359K 0.08% 367
2026
Q1 		$316K Buy
+22,731
New +$312K 0.04% 587

Other funds holding JANX

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $580M AUM 29.81% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return

AXQ Capital's JANX Position: Q2 2026 in Review

AXQ Capital increased its Janux Therapeutics (JANX) stake by 109% in Q2 2026, buying an estimated $359K and bringing the position to 47,508 shares worth $730K. The position accounts for 0.08% of the portfolio, ranked #367.

AXQ Capital first reported a position in JANX in Q1 2026 and has held it in 2 quarters since. 198 funds tracked by Wall St. Rank hold JANX as of Q2 2026.

  • AXQ Capital held 47,508 shares of Janux Therapeutics worth $730K as of Q2 2026.
  • AXQ Capital bought 24,777 Janux Therapeutics shares in Q2 2026, an estimated $359K.
  • Janux Therapeutics made up 0.08% of AXQ Capital's portfolio in Q2 2026, its #367 holding.
  • AXQ Capital first reported a position in Janux Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 198 funds tracked by Wall St. Rank held Janux Therapeutics as of Q2 2026.

Based on AXQ Capital's 13F filing for Q2 2026, filed 6 Aug 2026.